HCA Healthcare Q3 2026 Earnings: Payer Mix Pressure Offsets Volume Growth

HCA Healthcare (NYSE: HCA) reported Q3 2026 revenue of $19.849 billion, up 3.6% year over year, while diluted EPS rose 4.5% to $7.27. Net income attributable to HCA fell 3.9% to $1.579 billion as higher uninsured volume created an estimated $400 million unfavorable pre-tax impact, even as same-facility equivalent admissions grew 3.0% and operating cash flow reached $4.461 billion.

Core Earnings Results

Revenue increased by $688 million and adjusted EBITDA rose by $48 million, but income before taxes declined by $48 million. The quarter included a $13 million gain on facility sales, equal to $0.05 per diluted share, compared with a $2 million loss a year earlier.

Diluted EPS moved in the opposite direction from net income because diluted weighted-average shares fell about 8.0% to 217.2 million. HCA’s share repurchases contributed to this lower share count.

Adjusted diluted EPS and adjusted EBITDA are non-GAAP measures.

Operating Trends

Patient volumes improved overall, but the service mix remained uneven. Admissions and emergency room visits increased, while both inpatient and outpatient surgical cases declined.

The combination of 3.0% equivalent-admission growth and only 0.6% growth in revenue per equivalent admission shows that volume, rather than revenue per patient, was the main driver of quarterly revenue growth.

Higher Uninsured Volume Turned Patient Growth Into Weaker Margins

HCA experienced a payer mix shift toward uninsured patients, primarily because some patients lost coverage through health insurance exchanges. The company estimated that this change reduced third-quarter income before taxes by approximately $400 million.

That estimated impact was substantially larger than the reported $48 million decline in pre-tax income. HCA said accelerated equivalent-admission growth, improved insured revenue per equivalent admission excluding Medicaid supplemental payment programs, better cost results, and a modest increase in the net benefit from Medicaid supplemental programs offset much of the pressure.

Cost ratios were mixed. Salaries and benefits declined to 43.2% of revenue from 43.6%, while supplies decreased to 14.2% from 14.5%. Other operating expenses, however, increased to 23.0% of revenue from 21.8%, and the pre-tax margin narrowed to 11.9% from 12.6%.

Cash Flow, Leverage, and Capital Returns

Quarterly operating cash flow increased modestly to $4.461 billion. Capital expenditures excluding acquisitions totaled $1.357 billion, leaving approximately $3.10 billion after capital spending; this is a simple operating cash flow less capital expenditures calculation, not a company-reported free cash flow measure.

At September 30, HCA held $908 million of cash and cash equivalents against $50.493 billion of total debt. It also had $2.226 billion available under its credit facility. Interest expense rose to $607 million from $561 million in the prior-year quarter.

HCA repurchased 7.230 million shares for $2.970 billion during the quarter and had $4.240 billion remaining under its authorization. The board also declared a quarterly dividend of $0.78 per share, payable on December 29, 2026, to shareholders of record on December 15.

2026 Guidance

HCA now expects full-year operating results to fall in the upper half of the 2026 guidance ranges issued on July 14. The release did not reproduce the numerical endpoints, so the update provides a more favorable position within the existing ranges rather than a new set of disclosed figures.

The outlook assumes continued volume growth, a mostly stable operating environment, current payer and service mix expectations, resiliency initiatives, and anticipated effects from healthcare policy, inflation, and tariffs. It excludes future approvals that could affect certain state Medicaid directed and supplemental payments.

Recent Insider Transactions

The supplied six-month summary reported no insider purchases. Among the latest 10 supplied records, nine were zero-price stock grants or gifts; only one included a non-zero transaction amount.

A single reported sale does not by itself indicate an insider’s view of HCA’s outlook.

Investor Risks to Watch

• Insurance coverage and payer mix: The estimated $400 million pre-tax impact from higher uninsured volume demonstrates how exchange coverage losses can offset patient growth.
• Healthcare policy and reimbursement: Exchange reforms, the expiration of enhanced premium tax credits, and changes to Medicaid supplemental programs could affect coverage levels and reimbursement.
• Service mix: Same-facility inpatient and outpatient surgeries declined even as emergency room visits increased, which may continue to limit revenue growth per equivalent admission.
• Expense pressure: Other operating expenses rose faster than revenue, while interest expense increased year over year despite improvements in salary and supply cost ratios.
• Leverage and capital allocation: Total debt of $50.493 billion remained high relative to cash, while HCA continued substantial share repurchases and capital spending.

Summary

HCA’s Q3 2026 results combined higher patient volumes, revenue, EPS, and operating cash flow with lower net income and narrower margins. The central issue was a shift toward uninsured patients, which prevented stronger admissions from translating into comparable profit growth. Investors will need to monitor payer mix, surgery volumes, expense control, and whether HCA can deliver results in the upper half of its existing full-year guidance ranges.